深静脉血栓在2019冠状病毒病患者中的发生率及其对结局的影响
本研究为单中心1级创伤中心的回顾性观察性队列研究,比较573例非COVID-19患者与213例COVID-19患者的深静脉血栓(DVT)发生率及DVT对死亡率的影响。COVID-19组DVT和肺栓塞发生率分别为33.8%和7.0%,高于非COVID-19组的12.4%和3.3%;DVT是死亡的危险因素之一(OR 2.847,95%CI 1.356-5.5979)。作者认为需重新评估当前COVID-19患者的标准剂量血栓预防方案。
要点
- COVID-19患者DVT发生率为33.8%(72/213),高于非COVID-19患者的12.4%(71/573)。
- COVID-19合并ARDS患者DVT发生率为46.7%(28/60),高于非COVID-19合并ARDS患者的28.8%(44/153;P = .01)。
- DVT是死亡的独立危险因素(OR 2.847,95%CI 1.356-5.5979),作者建议重新评估标准剂量血栓预防。
核心结论
- 接受未按体重调整的标准剂量预防性抗凝的COVID-19患者DVT发生率较高,尤其是ICU患者。
- DVT是导致死亡率增加的的因素之一。
- 作者认为有必要重新评估当前针对COVID-19患者的标准剂量血栓预防方案。
研究设计与样本
- 单中心1级创伤中心的回顾性观察性队列研究,比较COVID-19患者与非COVID-19患者。
- 非COVID-19组573例(年龄61 ± 17岁;男性44.9%),治疗时间为2019年3月20日至2019年6月30日。
- COVID-19组213例(年龄61 ± 16岁;男性61.0%),治疗时间为2020年同期。
- 非COVID-19非ICU内科患者接受标准预防性抗凝为肝素5000 U每日三次;非COVID-19的ICU、外科和创伤患者接受依诺肝素40 mg每日一次(不按体重调整)。
- COVID-19患者无论是否在ICU均接受依诺肝素40 mg每日一次(不按体重调整)。
主要发现
- 非COVID-19组DVT发生率为12.4%(71/573),肺栓塞为3.3%(19/573);COVID-19组DVT发生率为33.8%(72/213),肺栓塞为7.0%(15/213)。
- 无诱因肺栓塞在COVID-19组为66.7%(10/15),在非COVID-19组为1.6%(8/497)。
- COVID-19合并ARDS患者DVT发生率为46.7%(28/60),非COVID-19合并ARDS患者为28.8%(44/153;P = .01)。
- COVID-19需ICU治疗患者DVT发生率为43.3%(39/90),非COVID-19需ICU治疗患者为33.3%(33/123;P = .01)。
- 死亡危险因素包括年龄(OR 1.030,95%CI 1.002-1.058)、DVT(OR 2.847,95%CI 1.356-5.5979)、多器官衰竭综合征(OR 4.438,95%CI 1.973-9.985)和延长通气支持(OR 5.321,95%CI 1.973-14.082)。
临床怎么用
- 作者认为,这些结果提示有必要重新评估当前针对COVID-19患者的标准剂量血栓预防方案。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Deep vein thrombosis (DVT) has been reported to occur at different rates in patients with coronavirus disease 2019 (COVID-19). Limited data exist regarding comparisons with non-COVID-19 patients with similar characteristics. Our objective was to compare the rates of DVT in patients with and without COVID-19 and to determine the effect of DVT on the outcomes. METHODS: We performed a retrospective, observational cohort study at a single-institution, level 1 trauma center comparing patients with and without COVID-19. The 573 non-COVID-19 patients (age, 61 ± 17 years; 44.9% male) had been treated from March 20, 2019 to June 30, 2019, and the 213 COVID-19 patients (age, 61 ± 16 years; 61.0% male) had been treated during the same interval in 2020. Standard prophylactic anticoagulation therapy consisted of 5000 U of heparin three times daily for the medical patients without COVID-19 who were not in the intensive care unit (ICU). The ICU, surgical, and trauma patients without COVID-19 had received 40 mg of enoxaparin daily (not adjusted to weight). The patients with COVID-19 had also received enoxaparin 40 mg daily (also not adjusted to weight), regardless of whether treated in the ICU. The two primary outcomes were the rate of deep vein thrombosis (DVT) in the COVID-19 group vs that in the historic control and the effect of DVT on mortality. The subgroup analyses included patients with adult respiratory distress syndrome (ARDS), pulmonary embolism (PE), and intensive care unit patients (ICU). RESULTS: The rate of DVT and PE for the non-COVID-19 patients was 12.4% (71 of 573) and 3.3% (19 of 573) compared with 33.8% (72 of 213) and 7.0% (15 of 213) for the COVID-19 patients, respectively. Unprovoked PE had developed in 10 of 15 COVID-19 patients (66.7%) compared with 8 of 497 non-COVID-19 patients (1.6%). The 60 COVID-19 patients with ARDS had had an incidence of DVT of 46.7% (n = 28). In contrast, the incidence of DVT for the 153 non-COVID-19 patients with ARDS was 28.8% (n = 44; P = .01). The COVID-19 patients requiring the ICU had had an increased rate of DVT (39 of 90; 43.3%) compared with the non-COVID-19 patients (33 of 123; 33.3%; P = .01). The risk factors for mortality included age, DVT, multiple organ failure syndrome, and prolonged ventilatory support with the following odd ratios: 1.030 (95% confidence interval [CI], 1.002-1.058), 2.847 (95% CI, 1.356-5.5979), 4.438 (95% CI, 1.973-9.985), and 5.321 (95% CI, 1.973-14.082), respectively. CONCLUSIONS: The incidence of DVT for COVID-19 patients receiving standard-dose prophylactic anticoagulation that was not weight adjusted was high, especially for ICU patients. DVT is one of the factors contributing to increased mortality. These results suggest a reevaluation is necessary of the present standard-dose thromboprophylaxis for patients with COVID-19.
引用
- Marini CP, Lewis E, Petrone P, et al. Incidence and effects of deep vein thrombosis on the outcome of patients with coronavirus disease 2019 infection. J Vasc Surg Venous Lymphat Disord. 2021. PMID: 34775121. doi:10.1016/j.jvsv.2021.10.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。